Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Natera Announces Launch of Panorama™ NIPT in Portugal and Thailand

Published: Wednesday, March 19, 2014
Last Updated: Wednesday, March 19, 2014
Bookmark and Share
Company announces two new partnerships to launch Panorama™ outside of the US.

Natera, Inc. has announced two new partnerships to launch its Panorama™ non-invasive prenatal screening test (NIPT) outside of the United States.

The Joaquim Chaves Group will manage the distribution of Panorama in Portugal, and Bangkok Cytogenetics Center will manage its distribution in Thailand.

“There is a strong demand for accurate and comprehensive prenatal screening tests outside of the U.S., and these two partnerships are an integral part of our mission to fill this need worldwide,” said Matthew Rabinowitz, Ph.D., chief executive officer of Natera.

Panorama™ has been validated globally in multiple clinical trials and has consistently demonstrated high sensitivity and specificity for all major aneuploidies beyond Down syndrome, including trisomy 13 (Patau syndrome) and 18 (Edwards syndrome), as well as sex chromosome abnormalities.

Panorama is also the only commercially available NIPT capable of screening for triploidy. A severe chromosomal syndrome, triploidy occurs in over 10% of spontaneous miscarriages. In some cases, it can be associated with persistent gestational trophoblastic neoplasia that may require close and ongoing physician follow up to ensure the best maternal outcome possible.

“Prenatal genetic screening and diagnosis is the focus of the Joaquim Chaves Group’s genetics department,” said Ana Rita Tarelho from the Clinical Genetics Department at Joaquim Chaves Group. “We have a history of being the first and striving for excellence in all of our work, so it is only natural for us to use Panorama, the most accurate non-invasive prenatal test in the market.”

Dr. Vitaya Titapant, the chief of the Maternal-Fetal Medicine Unit, Department of Obstetrics/Gynecology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand, said, “Fetal abnormalities, particularly in older women, are a significant challenge for us. We have implemented a number of methods to screen for these abnormalities, however invasive methods, including CVS and amniocentesis, put patients at risk for miscarriage, and non-invasive serum screening has a low detection rate and a high false positive rate. After trying the various non-invasive prenatal tests on the market today, we have selected Panorama because of its advantages. We now expect that this screening test will be used more extensively all over Thailand.”

Panorama analyzes cell-free DNA in maternal blood using a simple blood draw and can be performed as early as nine weeks without any risk to the fetus. Panorama uses an advanced, bioinformatics-based algorithm called NATUS [Next-generation Aneuploidy Testing Using SNPs] that analyzes in a single reaction approximately 19,500 single nucleotide polymorphisms (SNPs), within the most informative portions of an individual’s DNA.

These SNPs are combined with genetic information from the parents and data from the Human Genome Project to generate hypotheses of the potential fetal genotypes. These billions of hypotheses are then compared to the actual cell-free DNA measurements to determine the presence or absence of a chromosomal abnormality in the fetus.

Panorama is the only NIPT commercially available using a SNP-based approach, delivering reliable result early in pregnancy even at fetal fractions as low as 3.8%, which is important as low fetal fractions affect up to 25% of pregnancies between 9 and 14 weeks of gestation.

In contrast to traditional genetic testing such as amniocentesis or chorionic villus sampling, Panorama causes no risk to the fetus.

In published clinical trials, Panorama has demonstrated a sensitivity of greater than 99% for trisomy 21, trisomy 18 and trisomy 13, 92% for monosomy X, and a less than 0.1% false positive rate for all syndromes tested.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
New Tool Uses 'Drug Spillover' to Match Cancer Patients with Treatments
Researchers have developed a new tool that improves the ability to match drugs to disease: the Kinase Addiction Ranker (KAR) predicts what genetics are truly driving the cancer in any population of cells and chooses the best "kinase inhibitor" to silence these dangerous genetic causes of disease.
HIV Susceptibility Linked to Little-Understood Immune Cell Class
High levels of diversity among immune cells called natural killer cells may strongly predispose people to infection by HIV, and may be driven by prior viral exposures, according to a new study.
Sweet Revenge Against Superbugs
A special type of synthetic sugar could be the latest weapon in the fight against superbugs.
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
Long-sought Discovery Fills in Missing Details of Cell 'Switchboard'
A biomedical breakthrough reveals never-before-seen details of the human body’s cellular switchboard that regulates sensory and hormonal responses.
Tracking Breast Cancer Before it Grows
A team of scientists led by University of Saskatchewan researcher Saroj Kumar is using cutting-edge Canadian Light Source techniques to screen and treat breast cancer at its earliest changes.
Zebrafish Reveal Drugs that may Improve Bone Marrow Transplant
Compounds boost stem cell engraftment; could allow more matches for patients with cancer and blood diseases.
DNA Damage Seen in Patients Undergoing CT Scanning
Along with the burgeoning use of advanced medical imaging tests over the past decade have come rising public health concerns about possible links between low-dose radiation and cancer.
The Light of Fireflies for Medical Diagnostics
EPFL scientists have exploited the light of fireflies in a new method that detects biological molecules without the need for complex devices and high costs.
Vital Protein in Healthy Fertilization Process Identified
Researchers at the National Institutes of Health have discovered a protein that plays a vital role in healthy egg-sperm union in mice.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!